• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
QIU Yanyi,ZHOU Xiaohui.Formation mechanism and researth progress on the immunotherapy of castrate-resistant prostate cancer[J].Journal Of Pharmaceutical Research,2024,43(7):671-676[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3539times   Download 3776次 QR Code for this article
Scan with your phone!
去势抵抗性前列腺癌(CRPC)的形成机制及其免疫治疗研究进展
邱衍怡,周晓辉
Font:Larger+|Default|Smaller-
(中国药科大学,江苏 南京 211198)
摘要:
前列腺癌(prostate cancer,PCa)是困扰全球男性的恶性生殖系统疾病,疾病起始阶段对雄激素剥夺疗法(ADT)表现出良好应答。然而,患者不可避免地出现激素抵抗,从而进展为去势抵抗性前列腺癌(CRPC),极大降低患者生存率。临床上对CRPC研究主要围绕雄激素受体(AR)展开,此外也存在AR旁路途径。本综述将围绕雄激素受体依赖与旁路两种途径,讨论CRPC的形成机制,以及针对CRPC患者的免疫治疗方案的研究进展。
关键词:  去势抵抗性前列腺癌  形成机制  雄激素受体  免疫疗法
DOI:10.13506/j.cnki.jpr.2024.07.009
基金项目:国家自然科学基金项目(No.82070781)
Publication Date:July 25, 2024
Formation mechanism and researth progress on the immunotherapy of castrate-resistant prostate cancer
QIU Yanyi,ZHOU Xiaohui
(China Pharmaceutical University,Nanjing 211198,China)
Abstract:
Prostate cancer (PCa) is a malignant reproductive disease that afflicts men worldwide, with a favourable response to androgen deprivation therapy (ADT) in the initial stages of the disease. However, patients inevitably develop hormonal resistance, which progresses to castrate-resistant prostate cancer (CRPC) and greatly reduces patient survival. Clinical studies of CRPC are mainly centred around the androgen receptor (AR), but AR bypass pathways also exist. Therefore, this review discussed the mechanism of CRPC formation and the progress of immunotherapeutic regimens for patients with CRPC, focusing on both androgen receptor-dependent and bypass pathways.
Key words:  Castrate-resistant Prostate cancer  Formation mechanism  Androgen receptor  Immunotherapy
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.